Company Overview of Celtaxsys, Inc.
Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded in 2007 and is based in Atlanta, Georgia.
201 17th Street
Atlanta, GA 30363
Founded in 2007
Key Executives for Celtaxsys, Inc.
Chief Executive Officer, President and Director
Founder and Chief Financial Officer
Vice President of Operations
Compensation as of Fiscal Year 2015.
Celtaxsys, Inc. Key Developments
Celtaxsys, Inc. Gains U.S. Food and Drug Administration Clearance for Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis
Jul 6 15
Celtaxsys, Inc. announced that it has gained clearance from the U.S. Food and Drug Administration (FDA) to begin a Phase 2 clinical trial of its drug candidate, acebilustat (CTX-4430), in adult CF patients in the US. The regulatory submissions to the health authorities in Europe will be filed soon after. This groundbreaking clinical study, testing the lung function preservation effects of once-daily oral acebilustat treatment over 48 weeks, was designed in consultation with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT). The trial will be conducted in partnership with the CFFT and is partially funded by the $5 million research award granted by the CFFT to Celtaxsys earlier in 2015.
Celtaxsys, Inc. Announces Board Appointments
Jun 8 15
Celtaxsys, Inc. announced the successful completion of a $40 million Series D financing led by Domain Partners VIII. Additional investors in the financing include Lumira Capital, RMI Partners, Masters Capital Management and the Georgia Research Alliance Venture Fund. In conjunction with the financing, Nicole Vitullo, Partner at Domain Associates, Gerry Brunk, Managing Director at Lumira Capital, and Maxim Gorbachev, Partner at RMI Partners will join the company's board of directors at this important juncture for the company.
Celtaxsys, Inc. Receives Regulatory Clearance to Commence the Phase 2 Trial for its Compound, CTX-4430
Apr 7 15
Celtaxsys, Inc. announced that it has received regulatory clearance to commence the phase 2 trial for its compound, CTX-4430, in patients with moderate to severe facial acne vulgaris. This approval triggers site engagement to screen and enroll appropriate patients with acne henceforth. This proof-of-concept study will assess the efficacy and safety of 100 mg CTX-4430 administered as a once daily oral dose for 12 weeks. Effects on inflammatory lesion counts will serve as the primary efficacy outcome. Effects on non-inflammatory lesion counts as well as an Investigator's Global Assessment (the physician's overall assessment of the patient's disease) will also be studied. This phase 2 acne vulgaris study will be conducted at approximately 10 sites in Australia and New Zealand with Dr. Lynda J Spelman, MBBS FACD as the Principal Investigator.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 3, 2015